Abstract 180P
Background
Intrahepatic cholangiocarcinoma(iCCA) is the second most common primary hepatic malignancy after hepatocellular carcinoma (HCC), and is also a highly malignant type of tumor. It is necessary to identify novel therapeutic targets.Histidine phosphatase LHPP were reported as a tumor suppressor for Hepatocellular Carcinoma and cervical cancer. And low level LHPP enhanced cell progression and tumor formation, and was associated with poor prognosis. So, we hypothesized that LHPP might be also related to the tumorigenesis of iCCA.
Methods
We analyzed the expression and clinical significance of LHPP in TCGA cohort and patient tissues. We transfected the iCCA cell lines with LHPP over-expression lentivirus or small interfering RNA. Cell proliferation were evaluated with the CCK-8 and colony formation assays. Cell apoptosis was evaluated by Annexin V/PI staining.Transwell assays were performed to assess cell invasion. Gene Set Enrichment Analysis (GSEA) was performed to enrich genes associated with LHPP. Markers of EMT and TGFβ/SMAD3 signaling pathway were evaluated by real-time PCR and western blotting.
Results
In this study, we found the mRNA and protein level of LHPP were downregulated in tumor tissues, and low level LHPP predicted a poor survival. LHPP overexpression suppressed RBE and HCCC-9810 cells growth and colony formation, and moderately promote cell apoptosis and EMT. In contrast, accumulated cell growth, colony formation, cell invasion and EMT were observed in LHPP knock down cells. We divided samples from the TCGA-CHOL cohort into two sub-group (LHPP_low and LHPP_High) by medina expression of LHPP, and found that TGFβ signaling pathway was significantly activated in LHPP_low group. The expression of TGFβ1 was negatively correlated with LHPP. We found that the expression of TGFβ1, TGFβ1R and p-SMAD3 were downregulated in LHPP overexpression cells, and these proteins were upregulated in LHPP down-expression cells.
Conclusions
We demonstrated that LHPP also serve as a suppressor gene to inhibit cell proliferation, cell invasion and EMT. And low level LHPP which was observed in tumor tissues predicted a poor survival. Mechanically, low level LHPP activate TGFβ/SMAD3 signaling pathway.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fudan University Shanghai Cancer Center.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract